Characterizing neoantigens for personalized cancer immunotherapy.

doi:10.1016/j.coi.2017.04.007

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Characterizing neoantigens for personalized cancer immunotherapy.

Current opinion in immunology - 1 Jun 2017

Capietto Aude-Hélène, Jhunjhunwala Suchit, Delamarre Lélia

Abstract excerpt

Somatic mutations can generate neoantigens that are presented on MHC molecules and drive effective T cells responses against cancer. Mutation load in cancer patients predicts response to immune checkpoint blockade therapy. Additionally, vaccination targeting neoantigens controls established tumor growth in preclinical models. These recent findings led to a renewed interest in the field of cancer vaccines and the...

Topics

Algorithms
Antigen Presentation
Antigens, Neoplasm
Clonal Evolution
Endoplasmic Reticulum
Epitopes
Histocompatibility Antigens Class I
Humans
Immunotherapy
Mutation
Neoplasms
Peptides
Precision Medicine
Protein Binding
Protein Transport
Receptors, Antigen, T-Cell
T-Lymphocyte Subsets

Source

Open in PubMed

Identifiers

PMID: 28478383
DOI: 10.1016/j.coi.2017.04.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics